Portal de Periódicos da CAPES

Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders

2001; Elsevier BV; Volume: 22; Issue: 7 Linguagem: Inglês

10.1016/s0165-6147(00)01694-1

1873-3735

Will Spooren, F. Gasparini, T.E. Salt, Rainer Kühn,

Adenosine and Purinergic Signaling

Although multiple metabotropic glutamate (mglu) receptor subtypes were cloned in the early 1990s, progress in the characterization of these receptors has been slow because of difficulties in obtaining subtype-selective ligands. However, in the past few years exciting progress has been made on the mglu5 receptor subtype following the identification of selective non-amino-acid-like ligands that implicate the mglu5 receptor as a potentially important therapeutic target, particularly for the treatment of pain and anxiety.